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Abstract
Daily total water intake (TWI) has been linked to a number of chronic diseases, such as
urolithiasis and chronic kidney disease. Additionally, epidemiological and animal model
data have tied low TWI to impaired blood glucose regulation. However, the effect of a
fluid intake intervention on blood glucose regulation has not yet been observed in
humans.
PURPOSE: Thus, the purpose of the current investigation is to determine if the response
to an oral glucose tolerance test (OGTT) is altered by manipulation of hydration status in
people with diabetes. METHODS: Nine men (53±9 y, 94.9± 23.8 kg, 1.75± 0.11 m,
30.0± 4.3 m∙kg-2, 31.5± 6.5 %BF) who had previously been diagnosed with type II
diabetes mellitus (T2DM) (hemoglobin A1C; 6.8±0.9 %) were recruited to take part.
Participants completed two OGTTs in a euhydrated and hypohydrated state one week
apart in a counterbalanced order. Euhydration was achieved by standard water
prescription in line with the dietary reference intakes for water, and hypohydration was
achieved through progressive water restriction over three days leading up to the OGTT.
Blood samples were taken at time points 0, 15, 30, 45, 60, 90, 120 min of the OGTT.
RESULTS: The changes in TWI in the three days before each trial resulted in
significantly lower body mass (-1.5±1.5 kg; p = 0.017) and increased urine specific
gravity (0.017±0.009; p = 0.001), and plasma osmolality (10±8 mmol∙kg-1). Repeated
measures analysis of variance identified a main effect of condition for blood glucose
concentration F[1,48] = 10.772, p = 0.011, but not for insulin concentration F[1,48] =
.657, p = 0.441. Insulin sensitivity calculated with the Matsuda index revealed attenuated
insulin sensitivity during the hypohydrated trial (3.4±3.2) versus the euhydrated trial
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(3.8±3.7; t[8] = 2.834, p = 0.022) CONCLUSION: Hypohydration elicits an acute,
negative effect on the blood glucose response to OGTT in men with T2DM. Although,
blood insulin did not change, blood glucose and insulin sensitivity were reduced during
the euhydrated trial. This suggests that inadequate TWI can negatively impact blood
glucose regulation via decreased insulin sensitivity.
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INTRODUCTION
Type II diabetes mellitus (T2DM) is a costly disease that greatly reduces the
quality of life. Estimated total cost of diabetes in the United States is $245 billion (17).
T2DM results from a combination of resistance to insulin and/or a deficiency in insulin
production (17). During a person’s lifetime, the risk that someone will develop type II
diabetes is 1 in 3 for males and 2 in 5 for females (17). T2DM increases the risk of
developing many chronic diseases. There were 4.2 million people diagnosed with T2DM
who subsequently developed diabetic retinopathy (7). A total of 228,924 people with
diabetes had kidney failure (7). A person with diabetes was found to be 1.8 times more
likely to have a heart attack than those without diabetes (7). These are only some of many
complications that can occur in people with type II diabetes mellitus.
Excessive thirst is a common comorbidity with T2DM. Glucose multiplies in the
bloodstream which causes the kidneys to lose their ability to reuptake glucose from
water. The osmotic pressure then becomes high and stops water from being absorbed
back into the bloodstream. This results in major dehydration and thirst. The normal thirst
mechanism includes intracellular and extracellular components. Intracellularly, when the
body is dehydrated, there is an increase in plasma osmotic pressure (20). This causes
stimulation of both pituitary release of ADH and brain thirst centers (20). The release of
ADH results in the reabsorption of water in the kidneys, while the stimulation of brain
thirst centers causes the urge to drink (20). The body should then return to a normal
hydration state (20). Extracellularly, when the body is dehydrated, there is a decrease in
plasma volume (and in blood pressure) (20). This causes stimulation of specialized
volume receptors that leads to an increase in blood levels of angiotensin II, which leads to
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the stimulation of pituitary release of ADH, brain thirst centers, and aldosterone release
(20). The release of ADH and angiotensin II results in temporary vasoconstriction (20).
Reabsorption of sodium in the kidney occurs after aldosterone is released (20). Ideally,
the body will then return to a normal hydration state (20).
The renin-angiotensin system has become an important focus in the treatment of
hypertension (13). Although vasopressin is not directly part of the renin-angiotensin
system, it acts indirectly by inhibiting the release of renin by the kidney (19). Serious
depletions in water volume can effect secretions of vasopressin by the renin-angiotensin
(3). Vasopressin, the fluid regulatory hormone, has been experimentally linked to blood
glucose regulation in animal models (5). Furthermore, previous research has shown an
association between vasopressin and diabetes (18). Vasopressin has also been observed to
be linked to kidney dysfunction in type II diabetic mellitus patients (21). Measuring
copeptin, the stable COOH-terminal portion of the precursor of vasopressin, is effective
in determining vasopressin levels (16). As expected, elevated amounts of copeptin are
associated with heightened risk for diabetes mellitus (9). Hydration status is known to
determine the amount of vasopressin and copeptin secretion (16).
Low insulin sensitivity, also known as insulin resistance, is a characteristic of
people with type II diabetes mellitus (8). Many different techniques can be used to
predict insulin sensitivity. One effective way of measuring insulin resistance is by using
the homeostasis model assessment-insulin resistant (HOMA-IR) (11). HOMA-IR predicts
homeostatic concentrations that emerge from differing degrees of insulin resistance (15).
The Matsuda index of insulin sensitivity predicts whole body insulin sensitivity during an
oral glucose tolerance test (14). QUICKI is a reliable index of insulin sensitivity to
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determine hepatic insulin resistance (12). While, the Abdul-Ghani index of insulin
sensitivity predicts muscular insulin resistance (1).
Therefore, the purpose of the present investigation was to determine the effects of
mild hypohydration on glucose tolerance within individuals diagnosed with type II
diabetes mellitus (T2DM). Subsequently, our aim was to evaluate blood glucose levels
over two 120 minute time periods while in euhydrated and hypohydrated states.
Hypohydration must not be confused with dehydration. Hypohydration refers to a status
with maximum (minimum) urine osmolality, while dehydration refers to an acute process
of loss (gain) of total body water (10). We hypothesized that individuals in a
hypohydrated state would achieve blood sugar homeostasis for a longer period of time
than those in a euhydrated state after an oral glucose tolerance test. The current protocol
systematically modified fluid intake in order to investigate the hypothesis.

RESEARCH DESIGN AND METHODS
Participants
We studied nine males, previously diagnosed with type II diabetes from Northwest
Arkansas. Participation of the study was based on a certain criteria. The inclusion criteria
included: (a) males of ages 18-65 years old, (b) signed informed consent prior to the
initiation of any trial procedure, (c) sedentary lifestyle, (d) previously diagnosed as
having T2DM (confirmation of diabetic status during screening visit by glycosylated
hemoglobin concentration (HbA1c) ≥ 6.5%). The exclusion criteria included: (a) BMI
greater than 35 kg/m2 , (b) inability to participate in the entire study, (c) changes in diet
during the last month, (d) drastic change in weight in the last month (more than 3 kg), (e)
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inability or lack of desire to discontinue glucose regulating, diuretics, and/or renal (ACE
inhibitor) medications for the three days prior to, and the day of each experimental visit,
(f) serotonin re-uptake inhibitors (i.e. Prozac), (g) diabetic medication other than
Metformin or sulfonylureas, (h) impaired kidney or liver function, and (i) insulin therapy.
Procedures
Each participant had four visits to the Human Performance Laboratory at the University
of Arkansas over a period of two weeks. These visits included one
screening/familiarization visit, two experimental days, and one pre-dehydration visit. One
experimental day consisted of the participant coming to the lab in a euhydrated state and
the other experimental day in a hypohydrated state. The pre-dehydration visit occurred
exactly one day before the hypohydrated experimental day.
Screening and Consent
A certified nurse initially met with each participant to ensure qualification to participate
in the study. The nurse confirmed each participant was able to withdraw from any
medications for three days prior to both experimental days. The participants read the
consent form and were able to have their questions answered by the nurse. Next, the
participants completed a medical history form. Anthropomorphic measurements (i.e.,
height, weight, waist & hip circumference and body composition via DXA) were
recorded after receiving consent. To determine glycosylated hemoglobin (HbA1c) and
creatinine, a blood sample from a finger stick was performed and analyzed. The
participants were required to possess a value ≥6.5% to be involved in the study. The
criteria for diagnosis of T2DM is a value ≥6.5% (2). After qualification was confirmed,
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each participant was familiarized with the perceptual scales, filled out a water frequency
questionnaire, and practiced the static balance assessment (SBA) protocol.
Dietary control 3 days prior to experimental days
Each participant’s diet was controlled 3 days before the experimental days. A list was
provided to the participants for them to choose acceptable low water foods while
consuming 150 grams of carbohydrates each day (6). The participants were asked to
record their diet 3 days before the first experimental day and to replicate their diet for the
second experimental day. Thus, the fluid intake was the only difference between the
experimental days. Approximately 45 mL/kg of water were provided for the euhydrated
trial, while approximately 5 mL/kg of water were prescribed for the hypohydrated trial.
Participants were told to refrain from alcohol and caffeine for 24 hours prior to each
experimental day in order to elicit approximately 1-2% dehydration while controlling for
food within participants.
Experimental days
Participants reported to the lab on two days, separated by at least a week, in a fasted state
(i.e. no consumption of calories from food or beverage for the previous 9 hours) for the
main experimental visits. Typically for the first visit, the participant arrived in a
euhydrated state, while for the second visit, the participant arrived in a hypohydrated
state. However, this was not always the case. Some of the participants arrived in a
hypohydrated state for the first visit and a euhydrated state for the second visit. This
allowed for the experiment to be counterbalanced. As the participant entered the lab, a
urine sample was provided. Secondly, body weight was recorded to ensure hydration
status.
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Following, the patient settled in a specialized reclining chair designed for blood draws.
An oral glucose tolerance test (OGGT) was administered to evoke the classical insulin
and glucose responses following ingestion of dietary carbohydrates in a standardized
process. After 15 minutes of resting, a baseline blood sample was taken. Within 10
minutes of the initial draw, the patient consumed a standardized glucose beverage that
contained 75 grams of glucose. The patients then remained seated for the next 2 hours.
Blood samples of 15 mL were collected from the catheter at +15, +30, +45, +60, +90,
and +120 minutes from the time the standardized glucose beverage was consumed. The
total blood drawn equaled 90 mL, which is approximately 2.0% total blood volume.. The
remaining blood was centrifuged to separate the plasma. Plasma osmolality was
determined with freezing point depression. Further, electrolytes (Na+, K+, & Cl-) were
analyzed. The leftover blood plasma was stored in the freezer for later testing. After
observing differences between euhydrated and hypohydrated trials, analyses of secondary
markers were performed. These secondary analyses included renin, aldosterone, arginine,
vasopressin, and copeptin.

RESULTS
During this investigation, 9 men with T2DM were observed across a euhydrated trail and
a hypohydrated trial. Each participant was given a certain amount of water for the
euhydrated trial (3.5 L∙d-1) and hypohydrated trial (0.83 L∙d-1) (Table 1). To measure
glucose and insulin responses, fasting glucose, fasting insulin, HOMA-IR, Matsuda,
QUICKI, and Abdul-Ghani were recorded for each participant for both the euhydrated
and hypohydrated trials. Body mass, urine osmolality, and plasma osmolality were
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measured in each participant for both the euhydrated and hypohydrated trials to
determine hydration status before they started the OGTT. For the euhydration trial, the
average body mass was 95.1±23.8 kg, the average urine osmolality was 512±185
mmol∙kg-1, and the average plasma osmolality was 289±4 mmol∙kg-1 (Table 1). For the
hypohydration trial, the average body mass was 93.6±23.0 kg, the average urine
osmolality was 994±115 mmol∙kg-1, and the average plasma osmolality was 298±6
mmol∙kg-1 (Table 1).
Euhydration
Fasting glucose in the participants resulted in 9.9±4.1 mmol∙L-1. Fasting insulin in the
participants were 59.2±67.8 pmol∙L-1. HOMA-IR, ((fasting glucose×fasting
insulin)/22.5), predicted 5.7±5.2 for resting insulin resistance (15). Matsuda, (10,000 / √
fasting glucose×fasting insulin) × (mean OGTT glucose×mean OGTT insulin), predicted
3.8±3.7 for whole body insulin sensitivity during OGTT (14). QUICKI, (1/(log(fasting
insulin) + log(fasting glucose)), predicted 0.33±0.06 for hepatic insulin resistance (12).
Abdul-Ghani, (Glucose0-30(AUC) × Insulin0-30(AUC)), predicted 279±203 for muscular
insulin resistance (1) (Table 2). The area under the glucose curve was shown to be
1765±540 mmol∙L-1∙min-1 (Figure 1).
Hypohydration
Fasting glucose in the participants resulted in 10.4±4.2 mmol∙L-1. Fasting insulin in the
participants were 67.8±48.9. HOMA-IR, ((fasting glucose×fasting insulin)/22.5),
predicted 6.1±6.6 for resting insulin resistance (15). Matsuda, (10,000 / √fasting
glucose×fasting insulin) × (mean OGTT glucose×mean OGTT insulin), predicted 3.4±3.2
for whole body insulin sensitivity during OGTT (14). QUICKI, (1/(log(fasting insulin) +
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log(fasting glucose)), predicted 0.32±.05 for hepatic insulin resistance. Abdul-Ghani,
(Glucose0-30(AUC) × Insulin0-30(AUC)), predicted 282±203 for muscular insulin
resistance (1) (Table 2). The area under the glucose curve was shown to be 1862±560
mmol∙L-1∙min-1 (Figure 1).
Effect of Hydration Markers, Blood Glucose, and Insulin
The changes in total water intake in the three days before each trial resulted in
significantly lower body mass (-1.5±1.5 kg; p = 0.017), increased urine specific gravity
(0.017±0.009; p = 0.001), and plasma osmolality (10±8 mmol∙kg-1; p=0.003). Repeated
measures analysis of variance identified a main effect of condition for blood glucose
concentration F[1,48] = 10.772, p = 0.011, but not for insulin concentration F[1,48] =
.657, p = 0.441. Insulin sensitivity calculated with the Matsuda index revealed attenuated
insulin sensitivity during the hypohydrated trial (3.4±3.2) versus the euhydrated trial
(3.8±3.7; t[8] = 2.834, p = 0.022). A significant effect occurred with the QUICKI index
(p=0.007) but not for the Abdul-Ghani index (p=0.596).

DISCUSSION
This investigation sought to differentiate between euhydrated and hypohydrated
states and the effect each state has on glucose regulation of adult men with type II
diabetes mellitus. The primary findings were: 1) that reduced water consumption resulted
in increased glucose concentration before and during oral glucose tolerance testing, 2) no
changes in fasting or stimulated insulin occurred between trials, 3) glucose kinetic
calculations revealed that reduced water intake effected insulin sensitivity only during the
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OGTT, and 4) glucose regulation impairment appears to take place in the liver rather than
in the muscle tissue.
We expected a significant difference for urine osmolality (0.017±0.009; p =
0.001) and urine specific gravity (0.017±0.009; p = 0.001) as markers of hydration status.
Previous studies have shown that urine osmolality and urine specific gravity are reliable
in order to determine hydration status (4). We also expected the area under the glucose
curve for the euhydrated trial (1765±540 mmol∙L-1∙min-1) to be significantly different
than the hypohydrated trial (1862±560 mmol∙L-1∙min-1). Comparable research suggests
that hydration status can prevent the onset of T2DM (18). However, in our study, we
found there to be no significant difference between the areas of the glucose curves. A
significant difference occurred as expected for the QUICKI index (p=0.007). Earlier
studies have linked hepatic insulin resistance with T2DM (8).
This study has several limiting factors. The current investigation applies
specifically to men with T2DM. Also, no males under the age of 18 were allowed to
participate. Another limitation was having a small sample size. Having a larger sample
size would ensure a better representation of the target population.
Based on the information we know now, future research opportunities could help
determine the relationship between hydration state and glucose regulation in people with
T2DM. Future research should look to investigate glucose regulation in females with
T2DM in a euhydrated and hypohydrated state. This could potentially yield differing
results that could lead to positive repercussions in the long run for females with T2DM.
Also, future research should aim to establish if longer periods of fluid restriction results
in larger disturbances to blood glucose regulation.
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Water prescription*

Euhydrated

Hypohydrated

P-Value

3.5

0.83

<0.001

95.1 ± 23.8

93.6 ± 23.0

0.017

512 ± 185

944 ± 115

0.002

289 ± 4

298 ± 6

0.003

(L·dˉ¹)
Body mass
(kg)
Urine Osmolality
(mmol·kgˉ¹)
Plasma Osmolality
(mmol·kgˉ¹)

Table 1. Markers of hydration between euhydrated and hypohydrated conditions.
* – Average of prescribed bottled water intake on the three days leading up to the oral
glucose tolerance test.
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Variable

Predicts

Fasting glucose

Euhydrated

Hypohydrated

P-Value

9.9 ± 4.1

10.4 ± 4.2

0.037

59.2 ± 67.8

67.8 ± 48.9

0.155

(mmol·Lˉ¹)
Fasting Insulin
(pmol·Lˉ¹)
HOMA-IR

Resting insulin resistance

5.7 ± 5.2

6.1 ± 6.6

0.750

Matsuda

Whole body insulin sensitivity

3.8 ± 3.7

3.4 ± 3.2

0.022

during OGTT
QUICKI

Hepatic insulin resistance

0.33 ± 0.06

0.32 ± 0.05

0.007

Abdul-Ghani

Muscular insulin resistance

279 ± 203

282 ± 203

0.596

(in thousands)

Table 2. Fasting plasma glucose, insulin, and calculated indexes of insulin sensitivity.


HOMA-IR = (fasting glucose × fasting insulin) / 22.5



Matsuda = 10,000 / √(fasting glucose × fasting insulin) × (mean OGTT glucose
× mean OGTT insulin)



QUICKI = 1/(log(fasting insulin) + log(fasting glucose)



Abdul-Ghani5 = Glucose0-30(AUC) × Insulin0-30(AUC)

18
REFERENCES
1. Abdul-Ghani, M. A., Matsuda, M., Balas, B., & DeFronzo, R. A. (2007). Muscle
and liver insulin resistance indexes derived from the oral glucose tolerance
test. Diabetes care, 30(1), 89-94.
2. American Diabetes Association. (2014). Diagnosis and classification of
diabetes mellitus. Diabetes Care, 37(1), 81-90.
3. Andersson, B., Leksell, L. G., & Rundgren, M. (1982). Regulation of water
intake. Annual review of nutrition, 2(1), 73-89.
4. Armstrong, L. E., Maresh, C. M., Castellani, J. W., Bergeron, M. F., Kenefick, R.
W., LaGasse, K. E., & Riebe, D. (1994). Urinary indices of hydration status.
International journal of sport nutrition, 4(3), 265-279.
5. Bankir, L., Bouby, N., & Ritz, E. (2013). Vasopressin: a novel target for the
prevention and retardation of kidney disease?. Nature Reviews Nephrology, 9(4),
223-239
6. Conn, J. W. (1940). The necessity of a standard preparatory diet. The
American Journal of the Medical Sciences, 199(4), 555-563.
7. Centers for Disease Control and Prevention. (2014). National diabetes statistics
report: estimates of diabetes and its burden in the United States, 2014. Atlanta,
GA: US Department of Health and Human Services.
8. DeFronzo, R. A., Simonson, D., & Ferrannini, E. (1982). Hepatic and peripheral
insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1
(insulin-dependent) diabetes mellitus. Diabetologia, 23(4), 313-319.

19
9. Enhörning, S., Wang, T. J., Nilsson, P. M., Almgren, P., Hedblad, B., Berglund,
G., Struck, J., Morgenthaler, N. G., Bergmann, A., Lindholm, E., Groop, L.,
Lyssenko, V., Orho-Melander, M., Newton-Cheh, C., & Melander, O. (2010).
Plasma copeptin and the risk of diabetes mellitus. Circulation, 121(19), 21022108.
10. European Journal of Clinical Nutrition (2003). Summary and outlook. 57, Suppl
2, S96–S100. doi:10.1038/sj.ejcn.1601908
11. Katsuki, A., Sumida, Y., Gabazza, E. C., Murashima, S., Furuta, M., ArakiSasaki, R., Hori, Y., Yano, Y., & Adachi, Y. (2001). Homeostasis model
assessment is a reliable indicator of insulin resistance during follow-up of patients
with type 2 diabetes. Diabetes care, 24(2), 362-365.
12. Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G.,
& Quon, M. J. (2000). Quantitative insulin sensitivity check index: a simple,
accurate method for assessing insulin sensitivity in humans. The Journal of
Clinical Endocrinology & Metabolism, 85(7), 2402-2410.
13. Laragh J. (2001). Laragh's lessons in pathophysiology and clinical pearls for
treating hypertension. Am J Hypertens, 14(1), 84–9.
14. Matsuda, M., & DeFronzo, R. A. (1999). Insulin sensitivity indices obtained from
oral glucose tolerance testing: comparison with the euglycemic insulin
clamp. Diabetes care, 22(9), 1462-1470.
15. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., &
Turner, R. C. (1985). Homeostasis model assessment: insulin resistance and β-cell

20
function from fasting plasma glucose and insulin concentrations in
man. Diabetologia, 28(7), 412-419.
16. Meijer, E., Bakker, S. J., Halbesma, N., de Jong, P. E., Struck, J., & Gansevoort,
R. T. (2010). Copeptin, a surrogate marker of vasopressin, is associated with
microalbuminuria in a large population cohort. Kidney international, 77(1), 2936.
17. Narayan, K. V., Boyle, J. P., Thompson, T. J., Sorensen, S. W., & Williamson, D.
F. (2003). Lifetime risk for diabetes mellitus in the United States. Jama, 290(14),
1884-1890.
18. Roussel, R., Fezeu, L., Bouby, N., Balkau, B., Lantieri, O., Alhenc-Gelas, F.,
Marre, M., & Bankir, L. (2011). Low water intake and risk for new-onset
hyperglycemia. Diabetes care, 34(12), 2551-2554.
19. Share, L. (1979). Interrelations between vasopressin and the renin-angiotensin
system. Federation proceedings 38(9), 2267-2271.
20. Thornton, S. N. (2010). Thirst and hydration: Physiology and consequences of
dysfunction. Physiology & Behavior, 100(1), 15-21.
doi:10.1016/j.physbeh.2010.02.026
21. Velho G, Bouby N, Hadjadj S, Matallah N, Mohammedi K, Fumeron F, Potier L,
Bellili-Munoz N, Taveau C, Alhenc-Gelas F, Bankir L, Marre M, Roussel R.
(2013). Plasma copeptin and renal outcomes in patients with type 2 diabetes and
albuminuria. Diabetes Care. doi: 10.2337/dc13-0683.

21

